NSE: SOLARA | BSE: 541540

Mid-range Performer

Download real time

617.70 -3.10 (-0.50%)

30.03% Fall from 52W High

240.7K NSE+BSE Volume

NSE 27 Jun, 2025 3:31 PM (IST)

2,732.7

Market Cap

Above industry Median

1.1

Beta 1Year

High Volatility

Solara Active Pharma Sciences Ltd. share price target and research reports

Name: Latest research reports of Solara Active Pharma Sciences Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Solara Active Pharma Sciences Ltd.
Rating: 5
Author: Axis Direct

Latest analyst research reports with target prices and PDF download for SOLARA, BSE:541540 Solara Active Pharma Sciences Ltd.

Solara Active Pharma Sciences Ltd.

24 Nov 2020

617.70

-0.50%

Initiating Coverage:Solara Active

Buy: Solara Active Pharma Scien...

Axis Direct

We have initiating coverage on SOLARA with BUY rating and a target price of Rs 1,350 (P/E of 18x for FY23E earnings) which implies an upside of 25% from the current levels.

Solara Active Pharma Sciences Ltd. has gained 28.18% in the last 1 Month

Solara Active Pharma Sciences Ltd.

30 Oct 2020

617.70

-0.50%

SOLARA ACTIVE P

Buy: Solara Active Pharma Scien...

Sharekhan

Solara Active Pharma Sciences (Solara) has delivered its best-ever quarterly performance. Results are ahead of estimates. Sales at Rs. 397.6 crore grew by 13% y-o-y, backed by 17% y-o-y growth in regulated markets. Other markets reported 3% growth. Operating profit margin (OPM) stood at 24.5%, expanding impressively by 518 bps y-o-y, aided by 450 bps expansion in gross margin due to favourable product mix. Operating profit at Rs. 97.6 crore was up 43.5% y-o-y. PAT for the quarter stood at Rs. 56.7 crore, up 96.2% y-o-y and was ahead of estimates. Solara has proven capabilities to manufacture complex/combination active pharmaceutical ingredients (APIs). There are immense opportunities that have opened up for API players such as Solara. The company is witnessing...

Solara Active Pharma Sciences Ltd. is trading below its 200 day SMA of 622.9

Solara Active Pharma Sciences Ltd.

30 Oct 2020

617.70

-0.50%

SOLARA ACTIVE P

Buy: Solara Active Pharma Scien...

Sharekhan

Promoters unpledged 6.10% of shares in last quarter. Total pledge stands at 34.64% of promoter holdings

Solara Active Pharma Sciences Ltd.

19 Sep 2019

617.70

-0.50%

Solara Active Pharma Sciences (Update): Work in progress. NOT RATED

Not Rated: Solara Active Pharma Scien...

HDFC Securities

With 16/21/30% Sales/EBITDA/EPS CAGR and improved Adj. Net Debt/Equity ratio of 0.8x (v/s 1.4x in FY18), we believe the stock is trading at attractive valuations of 16/10x on FY20/21E P/E. However, the developing Ranitidine story related to NDMA impurities could be an overhang in the near term. If Solara successfully clears the impurity hurdles, it could turn out to be a big bonanza; else, sizable Ranitidine sales could be at risk. We assign a fair value of Rs 655 (15x FY21E EPS). We recently met the management of Solara and the company is on track to expand its API and CRAMS presence over the next three years. Long-lasting contracts in high-volume APIs will provide a solid base while high-value low-volume APIs and scale-up in the CRAMS business will drive both top-line growth and profitability. We believe a 15% CAGR in top-line and 20% CAGR in EBITDA looks achievable. The recent fundraising of Rs 4.6bn will be utilized in developing capabilities in both these segments

Solara Active Pharma Sciences Ltd. has gained 20.96% in the last 3 Months

Solara Active Pharma Sciences Ltd.

24 Jun 2019

617.70

-0.50%

Solara Active Pharma Sciences (Update): Pure API play. NOT RATED

Not Rated: Solara Active Pharma Scien...

HDFC Securities

At CMP, the stock is trading at 16.4/10.2x FY20/21E EPS, a ~30% discount to the sector-avg. We assign a fair value of Rs 650 (15x FY21E EPS). In light of environmental issues in China, the API market place is likely to present an enormous opportunity for established Indian API manufacturers. The global API market is close to US$ 160bn with China having a 30%+ market share, while India is at 8-10%. Solara is one of the leading API manufacturers in India having the capability to benefit from this opportunity due to a large API portfolio of 50+ molecules.

Number of FII/FPI investors decreased from 75 to 67 in Mar 2025 qtr

Solara Active Pharma Sciences Ltd.

20 Nov 2018

617.70

-0.50%

Solara Active Pharma Sciences (Visit Note): So far so good NOT RATED

Not Rated: Solara Active Pharma Scien...

HDFC Securities

Currently, the stock is trading at 9.2/6.6x FY18/19 EV/EBITDA, at a ~35% discount to peers. Sustained revenue growth, improving debt/EBITDA ratio and likely reduction in interest cost due to better credit rating to drive multiples in coming years. We recently met the Solara management and the company is confident in achieving its guidance of 15/20% YoY growth in revenue/EBITDA for FY19. So far, Solara has delivered 26/35% YoY growth in revenue/EBITDA in 1HFY19. Despite witnessing momentary pricing tailwinds in key products, Solara is expected to expand profitability over FY18-21E by higher asset utilization, new product launches and cost control post merger.

Promoters unpledged 6.10% of shares in last quarter. Total pledge stands at 34.64% of promoter holdings

Is Solara Active Pharma Sciences Ltd. worth buying?

180 Votes:

Buy 80.0%

Sell 13.89%

Hold 6.11%